Recce Pharmaceuticals (ASX: RCE) - The Science Behind R327 and the Phase 3 Review Ahead

Recce Pharmaceuticals has a synthetic polymer antibiotic, two Phase 3 trials, a new Australian licence and an independent data review due as soon as mid-November. This Insight explains what R327 is, what the trials have and have not shown, and how the cash, the debt and a contest for board seats fit around them.

Recce Pharmaceuticals (ASX: RCE) made two announcements in the space of three days in October 2026. On 20 October it told the market that an independent Data Monitoring Committee would look at unblinded results from 75 patients in its Indonesian Phase 3 trial of R327 gel for infected diabetic foot ulcers, with a meeting expected as soon as mid-November ^[R2]. On 22 October it signed a binding licence with Arrotex Pharmaceuticals to sell the gel in Australia and New Zealand once it is approved ^[R1].

Both announcements rest on one question, whether R327 gel does better than a placebo gel in a trial where neither the patients nor the doctors know who received which. The November review is the first step toward that answer. This Insight starts with the science, because the licences, the share raisings and the loan all depend on the trial results. It then works through the two Phase 3 trials, the regulators, the two licensing documents, the cash and debt, and the contest for board seats that comes to a vote at the annual general meeting on 6 November 2026.

Samso last wrote about Recce in May 2024, in Recce Pharmaceuticals surges nearly 50% as anti-infective pipeline advances. Since then Recce has started two Phase 3 trials, signed two licensing documents and taken on debt.

---

A NOTE ON THE VOCABULARY AND THE SOURCES

The technical terms are explained in plain English where they first appear. All of them are also collected in one box at the back, just above the references, for looking up again.

Each source carries a number, [R1] to [R30]. The same number appears in the text where that source is used, so any figure or quotation can be traced to the document behind it. Click a marker to jump to the source.

Where the company's documents give two different figures for the same thing, this article quotes both as they were published and names the document each came from. It does not attempt to resolve them. Where the article builds a model from released data rather than repeating a company statement, it says so at that point and labels it as a theoretical model. A model is not a prediction.

Where this Insight says a point has not been published, it means it is not in any of the documents listed in the references.

This piece quotes no prices at which the shares have traded. Every figure is dated by the document it comes from.

WHAT THIS PIECE COVERS

1.00 The problem R327 is aimed at

2.00 What R327 is and how Recce says it works

3.00 What has been tested in people

4.00 The Indonesian Phase 3 and the November review

5.00 The Australian Phase 3

6.00 The regulatory path

7.00 The market

8.00 The two licensing documents

9.00 Cash, debt and the going concern note

10.00 Shareholders, the board and the 6 November AGM

11.00 What comes next

· The vocabulary, in plain English

12.00 References and sources

1.00 — THE PROBLEM R327 IS AIMED AT

Infected diabetic foot ulcers, and why a new antibiotic gets attention

R327 gel is being tested on infected diabetic foot ulcers. A diabetic foot ulcer is an open sore, usually on the sole or toes, in a person whose diabetes has damaged the nerves or blood supply to the feet. Because the person often cannot feel the wound, it can go unnoticed. Bacteria then get in. When that happens doctors call it a diabetic foot infection, or DFI.

The international guideline doctors use is the 2023 guideline of the International Working Group on the Diabetic Foot and the Infectious Diseases Society of America, known as IWGDF/IDSA ^[R6]. In one large study the guideline cites, a year after presenting with an infected foot ulcer, 46 per cent of patients had healed, 15 per cent had died and 17 per cent had needed a lower limb amputation ^[R6]. The guideline calls diabetic foot infections the most frequent diabetes complication requiring hospitalisation and the most common event leading to lower limb amputation.

The guideline grades each infection as mild, moderate or severe, set out in TABLE 01. Recce's two Phase 3 trials enrol mild infections, and the Australian trial now takes moderate ones as well ^[R10]. The company says, citing a 2007 study, that mild and moderate infections together are about 80 per cent of all presentations ^[R4].

There is already a standard treatment. The IWGDF/IDSA guideline recommends antibiotic tablets or infusions chosen to match the likely bacteria ^[R6]. A mild skin and soft tissue infection is usually treated for one to two weeks, and a moderate or severe one for two to four weeks. The antibiotics go together with cleaning and cutting back the dead tissue, taking pressure off the foot and checking the blood supply. The guideline says that, apart from two studies, no antibiotic class has been shown to be better than the others for these infections.

The guideline suggests not using topical antibiotics, the kind applied to the skin, alongside tablets or infusions. It says the evidence does not support a benefit for most topical antiseptics or for silver, and that other topical agents showed only a marginal effect in low-quality studies ^[R6]. It also lists, as an open question, whether antimicrobials applied directly to the wound could reduce the use of antibiotics taken by mouth or vein. That open question is where Recce is aiming its gel.

The wider worry is antibiotic resistance. Most antibiotics work by attacking one specific part of the bacterium, such as an enzyme it needs to build its wall or copy its DNA. Recce's description is that they work like a lock and key ^[R3]. If a mutation changes that target, the antibiotic can no longer act on it and stops working. Bacteria that survive pass that mutation on.

A gel that kills the bacteria in a foot wound quickly, and that bacteria cannot easily learn to resist, would have a place in treatment. Whether R327 is that gel depends on evidence from the laboratory, then from small trials in people, then from the two Phase 3 trials.

2.00 — WHAT R327 IS AND HOW RECCE SAYS IT WORKS

A synthetic polymer designed to cut the bacterium's energy supply

R327 is a polymer, a large molecule built from many repeating chemical units. It is made entirely by chemical synthesis in a factory. Recce points out that most antibiotics were originally taken from a mould or a soil bacterium ^[R3]. The World Health Organization's 2025 review of antibiotics in development describes it as a fully synthetic acrolein polymer designed to disrupt bacterial energy production, cell growth and division ^[R5]. Acrolein is the small chemical building block the chain is made from.

Recce has two other compounds from the same chemistry. R435 is meant to be taken by mouth and R529 is aimed at viruses ^[R2]. R327 itself comes in two forms. R327G is the gel for wounds, and R327 is also being developed as an intravenous drip for blood and urinary infections ^{[R4] [R8]}. Both Phase 3 trials and both licensing documents are about the gel, so the rest of this Insight is about the gel.

The company describes R327's action in four stages, shown in FIG. 01. It binds to essential bacterial proteins, interferes with the cell's metabolism and energy production at or near the cell surface, kills without bursting the cell, and does so irreversibly ^[R4]. The energy in question is ATP, the molecule every living cell uses to power its chemistry. Recce's argument is that by attacking energy supply in several places at once, R327 gives bacteria no single target to mutate around.

The slide credits Linnaeus Biosciences, a contract laboratory, and cites a conference abstract. Recce's FY26 Annual Report says the company expects a peer-reviewed paper on the mechanism to be published in calendar 2026 ^[R8]. A peer-reviewed paper would let other scientists check the methods and repeat the work. Until then, the mechanism is as Recce describes it.

The resistance claim rests on a repeat-exposure test, shown in FIG. 02. In this kind of test bacteria are grown in a sub-lethal dose of a drug, and the survivors are grown again and again. If the bacteria adapt, the dose needed to stop them rises. In Recce's test, amoxicillin, a common penicillin, lost its activity within 2 to 8 rounds against E. coli, Pseudomonas aeruginosa (a common hospital bacterium) and Staphylococcus aureus (golden staph), while R327 stayed active beyond 25 rounds ^[R4]. The E. coli and golden staph rows are the like-for-like comparison. Pseudomonas aeruginosa is naturally resistant to amoxicillin and amoxicillin is not used to treat it, so that row tells us less about R327.

The March 2026 webinar presentation went further. It said R327 had not developed resistance in passaging experiments, the repeat-exposure test described above, run "100's of times". It also reported that none of 699 clinical strains supplied by the US Centers for Disease Control, many of them drug-resistant, was resistant to it ^[R28]. Laboratories decide whether a strain is resistant by comparing a result with a cut-off, which microbiologists call a breakpoint. Approved antibiotics have agreed breakpoints. A compound at R327's stage does not have one yet, which is usual, so the finding that none was resistant is the company's reading of its results. Publishing the data from the repeated runs would let other laboratories check it.

This laboratory work is encouraging and it is the reason the compound was taken into people. No resistance has been seen in Recce's tests so far. In drug development generally, laboratory resistance tests run for weeks while resistance in patients can take years to show up, so the longer answer comes from use in patients.

Recce also has animal work under way with the US military. In February 2026 it signed a Cooperative Research and Development Agreement with the US Army Institute of Surgical Research. It is Recce's second such agreement with the US Department of Defense. The work tests the gel on infected burn wounds in rats, against MRSA, the drug-resistant form of golden staph, and against Pseudomonas aeruginosa ^[R27]. Results from that work are still to come.

What the WHO review says about R327

Recce often cites its inclusion in the WHO's list of antibacterial agents in development ^[R2], and its place as the only compound in its category ^[R4]. Both are correct. The 2025 edition, published on 2 October 2025 with data to 15 February 2025, has an annex headed "ATP disruptors" with R327 as its only entry ^[R5].

The same report also scores every agent. For R327 it marks activity against each group of priority bacteria as "possibly active", and it marks all four of its tests for innovation (a new chemical class, a new target, a new mode of action and no cross-resistance with existing antibiotics) as "inconclusive data" ^[R5]. Its annex notes that the activity data come from posters and unpublished company data, and lists clinical study results as "Not yet publicly available".

In plain terms, the WHO has recorded R327 as a different kind of compound and has not yet been given enough published evidence to say whether it is a new class. The WHO's scores reflect how little has been published so far, and make no judgement on the molecule itself. A peer-reviewed mechanism paper and published trial results would let the WHO update those scores.

Recce makes R327 in its automated facility at Macquarie Park in Sydney. The company says the process has a 99.9 per cent product yield, meaning almost all of the raw material ends up as product. It says the raw materials cost a few dollars a kilogram. It also says the facility has produced 5,000 doses a week under Good Manufacturing Practice, the regulators' quality standard for medicines used in people ^{[R4] [R3]}. PLATE 01 is a photograph from the 2025 Annual Report showing Recce scientists at work.

3.00 — WHAT HAS BEEN TESTED IN PEOPLE

Small trials, all favourable, none yet testing the gel against a comparison group

R327 has so far been tested in people in a handful of small trials.

Medicines are tested in people in three phases before approval. Phase 1 gives the drug to a small number of people, often healthy volunteers, to check safety and dose. Phase 2 tests it in patients with the condition to get an early read on whether it works. Phase 3 is the large trial, usually comparing the drug with a placebo or an existing treatment, that a regulator relies on to approve it.

The intravenous form went first. A double-blind, placebo-controlled Phase 1 trial in healthy volunteers, described by the WHO as 80 healthy men, found R327 safe and well tolerated at doses up to 6,000 milligrams given over an hour, with no serious adverse events ^{[R5] [R4]}. Recce's website describes the same trial as having more than 60 participants on its urinary tract infection page and 80 subjects in eight dose groups on its FAQ page ^[R3].

Urine levels of the drug were up to 20 times the levels in blood, which is why Recce sees urinary infections as a natural use for the drip ^[R4]. A Phase 2 urinary infection trial was planned to begin in FY26 ^[R7]. The FY26 Annual Report says the company is "advancing plans" for it, and a start date is the next thing to look for ^[R8].

The gel was first tested in a Phase 1/2 study in patients with mild diabetic foot infections in south-western Sydney. The company says the study met its primary endpoints, the main results the trial was designed to measure. That was at an interim analysis, an early look at the results before the trial finished ^{[R28] [R3]}. Recce then ran a Phase 2 trial in acute bacterial skin and skin structure infections, or ABSSSI, a regulators' term for serious skin infections covering at least 75 square centimetres of skin. Recce describes that trial as covering ABSSSI including diabetic foot infections ^{[R3] [R10]}.

The Phase 2 results, reproduced in FIG. 03, are the main clinical results Recce has published for the gel. The trial enrolled 30 patients and analysed 29. After 7 days of treatment, 25 of the 29, or 86 per cent, had a successful clinical response. At 14 days, 27 of the 29, or 93 per cent, met the primary efficacy endpoint. There were no serious adverse events ^[R4].

The trial was open-label, meaning everyone, including the doctors scoring the wounds, knew every patient was getting R327 gel. There was no group on placebo or on a standard antibiotic ^{[R4] [R3]}. The trial shows the gel was well tolerated and that the patients got better. What a trial without a comparison group leaves open is how many would have got better without the gel. That is the question the Phase 3 trials are built to answer.

Recce also publishes case studies of patients treated under the Special Access Scheme of the Therapeutic Goods Administration (TGA), which lets a doctor use an unapproved medicine for a seriously ill patient. PLATE 02 shows before and after photographs from the June 2026 presentation. The company's website says such results "must be considered anecdotal" and are not part of any clinical trial ^[R3].

In April 2025 an ethics committee approved up to 20 more diabetic foot infection patients under the same open-label protocol ^[R7]. Results from that extension are still to come.

Taken together, the small trials show no serious safety findings for R327 and a high response rate in patients who all received it. What it does not yet have is a published result against a comparison group. The Indonesian Phase 3 trial is the first chance to see one.

4.00 — THE INDONESIAN PHASE 3 AND THE NOVEMBER REVIEW

The Indonesian Phase 3, and what the November review can and cannot show

The Indonesian trial, coded R327-G301, is Recce's most advanced study ^[R9]. It is overseen by Badan POM, Indonesia's food and drug regulator, which inspected one of its sites. On 21 April 2026 Recce reported that the inspection found nothing that would prevent the study from continuing ^[R9]. The trial runs at five sites in Jakarta, Surabaya and Denpasar, shown in FIG. 04 ^[R4].

It is a double-blind, placebo-controlled trial in patients with mild diabetic foot infections ^[R4]. Double-blind means neither the patients nor the doctors know who is getting the real gel and who is getting a placebo gel with no active drug. Placebo-controlled means the result is measured as the difference between the two groups. The 2025 Annual Report said two-thirds of patients would receive R327 gel and one-third placebo ^[R7]. That is the latest ratio Recce has published. Whether patients in either group also take antibiotic tablets alongside the gel is a detail still to be set out.

The primary endpoint is the clinical response of the infection on the Lipsky Scale ^[R8]. Dr Benjamin Lipsky was lead author of the Infectious Diseases Society of America's diabetic foot infection guidelines of 2004 and 2012, and the current guideline grades infection by clinical signs such as swelling, redness, warmth, tenderness and pus ^[R6]. A clinical response in this setting broadly means those signs have resolved or improved. FIG. 05 is Recce's summary of the design.

How the readout has been described

The size and timing of the first look at the results have been described several ways in Recce's documents, set out in FIG. 06. In the 2025 Annual Report, the trial targeted 300 patients with an interim analysis after 100 and a goal of accelerated approval in the first half of 2026 ^[R7]. From January 2026 the target was up to 310 patients, with what the company called an approvable interim data point at 155 ^[R13]. In April 2026, approval in Indonesia was "anticipated in CY26" ^[R9]. The general meeting presentation of 2 September 2026 put the interim readout in the third quarter of 2026 and commercialisation in 2027 ^[R30].

The release of 20 October 2026 describes something different again. A data set of 75 patients has been submitted to the Data Monitoring Committee for an ad hoc review. Ninety patients are enrolled, at a rate of 4.5 a week ^[R2]. Recce's website still describes an interim analysis after 155 of up to 310 patients ^[R3].

The following is Samso's arithmetic. At 4.5 patients a week, enrolment would need about another 14 weeks to go from 90 to 155 patients, which is late January 2027. Patients then need to complete treatment and follow-up before the 155-patient analysis could run. The 75-patient review gives an earlier look than the plan set out in January. The 20 October release does not say what prompted it.

What a Data Monitoring Committee does

A Data Monitoring Committee, or DMC, is a small group of independent experts, usually clinicians and a statistician, who are the only people allowed to see which patients received the drug while a trial is running. Their job is to protect patients and the trial's integrity. Recce's release lists four things the committee may recommend ^[R2]. It may recommend moving toward a regulatory submission if the safety and efficacy data support it. It may recommend continuing unchanged, or amending the protocol, for example its size or patient criteria. Or it may recommend pausing or stopping the trial for safety or futility. Futility means the trial is unlikely to show a difference even if it runs to the end.

The same release reports that a separate review of the blinded data, by infectious disease specialists, investigators and statisticians, showed "encouraging clinical outcomes across the study population, with a high proportion of patients experiencing either resolution or improvement of infection" ^[R2]. The first highlight of the release puts it more strongly. It says the review of blinded data "indicates strong efficacy across the study population". Chief Executive James Graham said in the same release that "R327G is anticipated to become the standard of care for the treatment of Diabetic Foot Ulcer Infections" ^[R2].

A high response rate across the whole group is a good sign that patients in the trial are doing well. A blinded review sees every patient in one pool. It cannot tell the R327 group from the placebo group, so a high pooled response rate is consistent with R327 working well and also with both groups doing well.

A worked example shows why, using made-up numbers and Recce's earlier two-to-one ratio. If 50 patients on R327 responded at 90 per cent and 25 on placebo at 60 per cent, the pool of 75 would show 80 per cent. If both groups responded at 80 per cent, the pool would also show 80 per cent. In the first case the drug makes a clear difference. In the second it makes no difference. Only the unblinded comparison the DMC is about to make can separate the two.

Each time a trial's unblinded results are examined, there is a fresh chance of a difference that looks real but is luck. Trials allow for this by setting a stricter bar in advance for any early look. The release calls this review ad hoc and also says the DMC process is built into the trial protocol ^[R2]. The bar for this particular look has not been published. With roughly 25 patients on placebo, if the earlier two-to-one ratio still holds, any gap between the groups is likely to carry a wide margin of error.

A similar topical drug has been tested in the same setting. In 2016 Dipexium Pharmaceuticals reported that two Phase 3 trials of pexiganan, an antimicrobial cream for mildly infected diabetic foot ulcers, did not meet their primary endpoint ^[R26]. The trials enrolled 389 patients at 59 US centres. The endpoint was beating a placebo cream when both groups received standard wound care. The IWGDF/IDSA guideline cites those two trials in its review of topical treatments ^[R6]. The design is close to Recce's Indonesian trial. In mild infections treated with good wound care, patients on placebo can do well. That makes a clear difference harder for a topical drug to show than an open-label response rate would suggest.

Pexiganan was a different molecule, so its result does not show how R327 will perform. It shows how high the bar is when the placebo group also gets good wound care. Recce's Australian trial uses a different test, comparing the gel with antibiotics rather than with a placebo.

THE COMPANY'S CASE, AND THE CASE FOR CAUTION

The company's case rests on more than one point. R327 is the only entry in the WHO's category of ATP disruptors ^[R5]. The intravenous form came through a double-blind, placebo-controlled Phase 1 trial with no serious adverse events at doses up to 6,000 milligrams ^{[R5] [R4]}. The gel has shown no serious safety findings in any trial so far ^{[R4] [R3] [R2]}. In the laboratory, bacteria did not adapt to R327 over more than 25 rounds of repeat exposure ^[R4].

Recce reported that the Badan POM inspection found nothing that would stop the Indonesian trial ^[R9]. A separate review of the blinded data found a high proportion of patients whose infection resolved or improved ^[R2]. Arrotex has signed a binding licence with no conditions precedent and will pay for the filings and marketing in Australia and New Zealand ^[R1]. The Australian trial asks whether the gel works as well as existing antibiotics, and a new antibiotic can pass that test without beating a placebo. The DMC may also recommend moving toward a submission ^[R2].

The caution rests on three points made above. The Phase 2 trial was open-label. A blinded pool cannot separate drug from placebo. And pexiganan did not beat a placebo cream in the same setting ^[R26].

The DMC's recommendation, when Recce announces it, will be the first independent read of R327 against a placebo. It may not include numbers. If the committee recommends continuing unchanged, the group results normally stay sealed so the trial is not compromised. In that case the market would learn little about whether the gel works, and that would not by itself be a bad sign.

5.00 — THE AUSTRALIAN PHASE 3

An Australian trial against existing antibiotics, aimed at the FDA

Recce's second Phase 3 trial is in Australia. It began as the Phase 2 trial and was elevated in June 2026, when an ethics committee approved a protocol change that Recce describes as making it a pivotal Phase 3 study, meaning one designed to support an application for approval. At that point 18 of an anticipated 200 patients had been treated. The amendment opened the trial to moderate as well as mild infections and to infected ulcers below the knee. Full enrolment was expected by the end of 2027 ^[R10].

The ethics approval is the first step. An ethics committee approves a trial on ethical and scientific grounds, and in the end it is the regulators who rely on a trial that decide whether it is pivotal. The next thing to watch is whether the FDA or the TGA has looked at the design, which Recce has not yet said.

In August 2026 a further amendment added a randomised comparison. A total of 208 patients will be randomly assigned either to R327 gel or to one of four antibiotics chosen by their doctor, with an interim analysis by the DMC after 104 patients ^[R11]. Recce's June 2026 presentation had labelled the Australian study placebo-controlled, and its July presentation changed the label to active comparator, meaning the gel is compared with existing antibiotics ^{[R4] [R29]}.

Recce has added calibrated wound photography to give a more objective measure alongside the doctors' assessment ^[R11]. That helps, because a gel is hard to disguise as a tablet or a drip. The releases do not yet say whether the doctors scoring the wounds will know which treatment each patient received.

The June amendment also added an analysis that counts individual ulcers as well as patients. Recce says this increases the study's statistical power, its chance of detecting a real difference ^[R10]. The August amendment lets patients on R327 gel be treated for each new qualifying infection during the study ^[R11]. How the patients treated before the comparison was added will be counted is still to be set out.

Comparing a new drug with existing antibiotics in this way is called a non-inferiority design. It tests whether R327 is no worse than an existing antibiotic by more than a margin agreed in advance. That is a common and accepted design for new antibiotics, because a new drug that works as well as existing ones, and that bacteria have not yet learned to resist, is useful in itself. The general meeting presentation adds that the design "includes a superiority analysis" ^[R30], a second test of whether R327 does better. The margin is normally agreed with the regulator before the trial reads out. Its size has not been published.

Recce says the Australian trial is run to the standards of both the TGA and the US Food and Drug Administration (FDA), and the FY26 Annual Report targets registration in Australia and the United States in 2028 ^[R8]. Before a drug can be tested in a US trial, the sponsor files an Investigational New Drug application, or IND, with the FDA. Recce's use of funds for its June 2026 raising, written on the basis of the full A$8.0 million, allocated A$2.0 million to work toward an Investigational New Drug application with the FDA and Badan POM. The raising brought in A$6.4 million ^[R19]. No date for an IND filing has been published. One condition attached to Recce's undrawn debt, discussed in section 9.00, is the dosing of the first patient in a US Phase 3 study ^[R8].

The Australian trial is the one designed to answer the question a Western regulator and a prescribing doctor will ask, which is how R327 compares with what is used today. Its interim analysis is some way off, at 104 patients, with full enrolment expected by the end of 2027.

6.00 — THE REGULATORY PATH

Indonesia first, then Saudi Arabia, Australia and the United States

Recce's plan is to seek approval in Indonesia first. Badan POM has given the trial what the company calls Expedited Regulatory Review status, a pathway the FY26 Annual Report describes as designed to help needed therapies reach approval quickly ^[R8]. The company says an Indonesian approval "opens access to 10 ASEAN member states, covering a population of 680 million" ^[R4]. An Indonesian approval would be a useful first step in the region. Each other country's regulator would ordinarily still expect an application, and the documents do not describe how an Indonesian approval would carry across.

For Saudi Arabia, Recce says that, subject to the Indonesian trial's outcome, no additional clinical trials are anticipated for a marketing application ^[R12]. The Saudi regulator's view has not been published.

In the United States, R327 holds Qualified Infectious Disease Product designation, granted by the FDA in 2017 for R327 in bacteraemia, a bacterial infection of the blood ^[R4]. That is the intravenous use. The designation comes from the Generating Antibiotic Incentives Now Act, or GAIN Act. Under the law, a designated drug that is later approved gets its period of market exclusivity extended by five years ^[R24]. The same law says the extension does not apply to a later application for a new indication, route of administration or dosage form of a product already approved ^[R24]. Whether the gel for diabetic foot infections holds a separate designation is the point to watch, because the extension follows the designated product. Recce has not said so yet.

Recce's June 2026 presentation and its releases describe the benefit as 10 years of market exclusivity ^{[R4] [R2]}. That matches the five-year exclusivity a new chemical entity, a medicine whose active ingredient has never been approved before, receives in the United States, plus the five-year extension. Recce's general meeting presentation, FY26 Annual Report and the About page of its website say five years, which matches the extension alone ^{[R30] [R8] [R3]}. The FAQ page of the same website says 10 years ^[R3]. Recce also says the designation gives R327 Fast Track status with the FDA ^[R4]. The exclusivity counts only after approval ^[R24]. Fast Track mainly affects how the FDA handles the development programme and the review.

In Australia, the Arrotex licence sets the order. Arrotex does not have to apply to the TGA until R327G is approved by the FDA, the European Medicines Agency (EMA) or another regulator the TGA recognises as comparable ^[R1]. Arrotex's obligation to file therefore follows a US, European or similar approval, not an Indonesian one.

The regulatory path is staged. Indonesia is the near-term test and depends on the Phase 3 data now under review. Saudi Arabia leans on the Indonesian data. Australia and the United States lean on the Australian trial, together with the US Phase 3 study noted in section 5.00, and a US IND filing for which no date has been published.

7.00 — THE MARKET

How many patients, and what the market estimates cover

The International Diabetes Federation estimates that 589 million adults aged 20 to 79 are living with diabetes, rising to 853 million by 2050 ^[R25]. Recce cites the federation for about 84 million adults with diabetes in the Middle East and North Africa and more than 20 million in Indonesia ^{[R4] [R12]}. In Australia, the Arrotex release says about 50,000 people are estimated to be living with a diabetes-related foot ulcer, with about 300,000 more at risk ^[R1].

Those figures count people with diabetes or with ulcers. Recce's June 2026 presentation cites Grand View Research for a global diabetic foot ulcer treatment market of US$5.8 billion ^[R4]. It is a third-party market report quoted by the company. It covers all diabetic foot ulcer treatment, of which a gel would be one part.

In Indonesia the company cites a 2024 study reporting average in-hospital costs for diabetic foot infection patients of IDR 64.95 million, about US$4,100, and amputation in 46.9 per cent of hospitalised patients ^[R4]. Hospital cases tend to be more severe than the mild infections the Indonesian trial enrols.

The market for a gel narrows in steps. It starts with the number of patients with an infected ulcer, then the share whose infection is mild or moderate, then the share a doctor would treat with a gel, then the price a payer accepts and Recce's share of that price. Recce has published figures for some of those steps and not others, and the last two are what section 8.00 turns to.

8.00 — THE TWO LICENSING DOCUMENTS

The Arrotex licence and the Middle East term sheet

Recce has two commercial documents for R327 gel. FIG. 07 sets their terms side by side.

Arrotex, Australia and New Zealand

The agreement with Arrotex Pharmaceuticals, signed on 22 October 2026, is binding and not subject to any conditions precedent ^[R1]. Arrotex describes itself as Australia's largest and most diversified pharmaceutical company and is part of DBG Health. It gets exclusive rights to register and sell R327 gel for diabetic foot infections and ABSSSI in Australia and New Zealand. Any new form of R327, such as an intravenous or inhaled one, would first go to good-faith negotiation. If the two companies do not agree terms within 90 days, Arrotex has a right of first refusal ^[R1].

Recce keeps the patents and manufactures the gel. Arrotex pays Recce its cost plus a margin for the gel, and that payment is credited against Recce's profit share. The profit share is described as "a significant profit share of the gross margin", meaning net sales less Recce's cost of goods, paid quarterly. The percentage is not disclosed. There are no upfront or milestone payments. Arrotex pays for Australian and New Zealand regulatory filings, the Pharmaceutical Benefits Scheme and Pharmac submissions, and sales and marketing ^[R1].

Dr Melinda Munns, Arrotex's Chief Medical Officer, said that "On approval, we expect R327G will represent an innovative approach to a serious and costly complication of diabetes" ^[R1]. The licence runs until the later of the last patent expiry and 10 years after the first Australian sale. Arrotex may terminate without penalty if Recce discontinues its FDA or EMA pathway.

The licence gives Recce an established local partner, which matters for a company of its size. It brings no cash now. Arrotex does not have to apply to the TGA until after an FDA, EMA or comparable approval ^[R1]. Recce targets US registration in 2028 ^[R8]. Australian sales would follow the TGA's review after that.

The Middle East term sheet

On 27 May 2026 Recce signed a non-binding term sheet with an unnamed Middle Eastern pharmaceutical company for a proposed 10-year exclusive licence ^[R12]. The partner is described as publicly listed, with a multi-billion-dollar market capitalisation and distribution in more than 30 markets. An addendum the same day said the company did not consider the partner's identity to be material, and that Recce's due diligence on the partner's audited accounts confirmed the partner's capacity to pay.

The proposed terms are an upfront fee and milestones totalling up to US$3.5 million, and a proposed price of US$1,500 per treatment ^[R12]. The share of sales is 30 per cent of the net selling price, with an extra 6 per cent royalty on annual net sales above US$50 million. The price is subject to agreement with the Saudi regulator. The territory named in the release is Saudi Arabia, the United Arab Emirates, Kuwait, Oman, Bahrain, Qatar, Iraq, Egypt, Algeria and Morocco, 10 countries in all, shown in FIG. 08. Recce's July presentation and FY26 Annual Report describe the territory as 12 ^{[R29] [R8]}.

The release said the parties were targeting a definitive agreement "next quarter", meaning the quarter to 30 September 2026 ^[R12]. The June quarterly report later targeted the fourth calendar quarter of 2026 ^[R15]. No definitive agreement had been announced at 22 October 2026.

FIG. 09 is a Samso theoretical model of what the proposed terms would pay. It is not a company forecast. At US$1,500 a treatment, 30 per cent is US$450. Net sales reach US$50 million a year at about 33,300 treatments, and beyond that the extra 6 per cent applies. On those assumptions 10,000 treatments a year would pay Recce about US$4.5 million, 20,000 about US$9 million and 40,000 about US$18.6 million.

The model shows the scale of what Recce's published terms would pay. The actual receipts would depend on four things. The term sheet is not binding and may change. The price needs the Saudi regulator's agreement. Net selling price, the base for the 30 per cent, is usually below a list price once discounts are taken off. And Recce makes and supplies the gel under the proposed terms ^[R12], so these figures are receipts before its manufacturing cost. How many treatments will be sold is the number still to come, and Recce has not yet published a forecast.

9.00 — CASH, DEBT AND THE GOING CONCERN NOTE

Cash at 30 June, the July inflows, a US$7.5 million loan and conditional funding

Recce's cash at bank has fallen from A$10.53 million at 30 June 2025 to A$2.90 million at 30 June 2026, according to its quarterly cash flow reports, shown in FIG. 10 ^{[R13] [R14] [R15]}. Its FY26 Annual Report gives cash of A$2,694,474 at 30 June 2026, against A$2,896,729 in the June quarter report ^{[R8] [R15]}. At 31 December 2025 the quarterly report gave A$424,591 and the half-year accounts gave A$365,256 ^{[R13] [R16]}. For 30 June 2025 the quarterly reports give A$10,533,995 and the FY26 Annual Report gives A$10,448,808 ^{[R15] [R8]}. All three pairs are quoted as published. The rest of this section uses the quarterly report figures.

For the year to 30 June 2026 Recce reported a loss of A$14.96 million and used A$9.89 million in its operations. At year end it had net liabilities of A$16.72 million ^[R8]. Trade and other payables of A$12.57 million included A$3.94 million of placement money received before 30 June for shares issued on 1 July, which became equity on that date. Amounts owed to suppliers were A$8.20 million ^[R8]. For a shareholder, that means Recce owed its suppliers more at 30 June than it held in cash.

The FY26 accounts book A$8.88 million of R&D tax incentive income. The FY26 claim is not booked. The FY26 Annual Report discloses it as a contingent asset and says the amount cannot yet be measured reliably ^[R8]. Recce's 1 July 2026 release put it at about A$7.5 million ^[R20]. Separately, on 1 July 2026 Recce announced it had received an A$3.7 million income tax refund for the year to 30 June 2025, mostly for overseas R&D spending ^[R20]. The FY26 Annual Report dates the receipt 2 July 2026 ^[R8]. The Australian R&D Tax Incentive refunds 43.5 per cent of eligible research spending, including approved overseas spending, which is why it is a large part of Recce's funding ^[R20].

The FY26 accounts carry a material uncertainty about Recce's ability to continue as a going concern, and the auditor, BDO, drew attention to it. Note 3 says the Group's ability to continue "is dependent on securing additional funding through a share placement to new or existing investors and financial support through short-term loans, together with continuous receipt of the R&D tax rebate" ^[R8]. The directors' view is that refinancing through equity "would be well supported" and that spending can be slowed if required. A similar going concern note appeared in the half-year accounts ^[R16].

BDO's paragraph is not a qualified audit opinion ^[R8]. The Annual Report also says the group expects to spend about US$8.98 million over the next 12 months on research organisations in the US and Indonesia and on US consultants ^[R8]. That is more than the cash it held at 30 June.

Equity raised in 2026

In June 2026 Recce placed 10 million shares at A$0.40 to raise A$4.0 million and offered a share purchase plan on the same terms. The plan raised about A$2.4 million against a target of A$4.0 million, taking the total to A$6.4 million before costs ^[R19]. The free attaching options promised to plan participants needed shareholder approval. Shareholders voted against it, as section 10.00 explains.

The Avenue Capital loan

Recce's debt is a facility from Avenue Capital Group, a New York investment firm, set out in TABLE 02 ^{[R17] [R18] [R8]}.

The undrawn US$12.5 million is the part the company counts in its funding figures. The quarterly reports include it in available funding, along with a smaller share placement facility. That is how the June quarter report arrives at 10.87 quarters of funding ^[R15]. The July presentation's pro-forma cash position of about A$33.1 million counts the debt "if debt component is drawn" along with expected tax refunds and an R&D advance ^{[R29] [R15]}.

On 16 October 2026 the interest-only period was extended to 31 December 2026, with options to extend to 30 September 2027 if Recce meets capital-raising targets and positive clinical milestones, which the release does not quantify. Avenue received 493,103 more warrants at A$0.29 ^[R18].

The FY26 Annual Report describes the undrawn amount as available until 31 December 2027, subject to drawdown conditions, while the October amendment gives 31 December 2026 for the second tranche ^{[R8] [R18]}. Both are quoted as published. If the interest-only period is not extended, the loan moves to equal monthly repayments of principal through to maturity ^[R17].

For a shareholder, Recce's cash at 30 June 2026 was A$2.9 million on the quarterly report. In July it received the A$3.7 million tax refund and about A$2.4 million from the share purchase plan ^{[R20] [R19]}. Beyond that it depends on the FY26 tax refund still to come and whatever equity it raises. The larger figures it publishes depend on events that have not happened yet, chiefly the Indonesian data and a new equity raising. Both depend heavily on the DMC outcome.

10.00 — SHAREHOLDERS, THE BOARD AND THE 6 NOVEMBER AGM

The largest shareholder has nominated four directors

Recce had 305,770,071 shares on issue and 4,354 holders at 20 August 2026 ^[R8]. Its largest registered holder was Mr Gavin William Brown with 40,195,981 shares, or 13.15 per cent. The family of the late founder Dr Graham Melrose held 28,353,311 shares, or 9.27 per cent, in its main holding. The top 20 holders had 52.68 per cent ^[R8]. Dr Melrose, a former head of research at Johnson & Johnson Asia Pacific and the inventor of the polymer platform, has died ^{[R8] [R3]}. Recce announced his death on 14 November 2025 ^[R8].

The board has six directors. Dr John Prendergast is Executive Chairman, James Graham is Managing Director and Chief Executive, Michele Dilizia and Dr Justin Ward are executive directors, and Dr Alan Dunton and Alistair McKeough are non-executive directors. The Annual Report counts two of the six as independent ^[R8].

The 2 September general meeting

At a general meeting on 2 September 2026 shareholders voted down all six resolutions, shown in FIG. 11 ^[R21]. Five sought approval to issue free attaching options to share purchase plan participants and to four directors, and the sixth sought to ratify the June placement shares. Proxies lodged before the meeting ran more than 90 per cent in favour, but about 41 million votes were cast against each resolution on the poll ^[R21]. The company said it was "considering the options available to it".

The failed ratification means the placement shares continue to count against the company's 15 per cent limit under ASX Listing Rule 7.1 for 12 months after they were issued, which reduces what it can issue without shareholder approval ^[R21]. The board is putting the same ratification to the AGM as Resolution 9. It is also seeking an extra 10 per cent capacity under Listing Rule 7.1A as Resolution 8, a special resolution that needs 75 per cent of the votes cast ^[R23].

The requisition and the nominations

On 25 September 2026 Mr Brown, as a holder of more than 5 per cent, gave Recce a notice under section 249N of the Corporations Act ^[R22]. It proposed a change to the constitution allowing shareholders to pass advisory resolutions. It also proposed a resolution asking the directors to set up an independent advisory council. The council would review, within 60 days, the clinical programs, commercial strategy, capital structure and funding, board and executive structure, and remuneration and consulting arrangements. Recce said it was "assessing the validity" of the proposals. Mr Brown also nominated four candidates for election as directors ^{[R22] [R23]}.

The notice of the 6 November AGM includes the four nominations, Ms Diana Forsyth, Mr Amos Meltzer, Dr Jurgen Michaelis and Dr Paul MacLeman, as Resolutions 2, 4, 5 and 7 ^[R23]. The board recommends voting against all four. It says the nominees' information "does not indicate extensive experience in developing or launching a new prescription drug product, or in US FDA regulatory matters". It also says four new directors at once could affect cohesion, and that four nominees from one shareholder could give him disproportionate influence. Each nominee's statement says they hold no Recce securities and have no relationship with the nominating shareholder ^[R23].

Among the nominees, Dr MacLeman chairs AdAlta, an ASX-listed company, and has served on the board of Island Pharmaceuticals, which Samso covered in Island Pharmaceuticals Strengthens Galidesivir Position. Mr Meltzer is a former chief executive of Immuron, also ASX-listed, and Dr Michaelis is a former vice president of commercial and business development at Bavarian Nordic ^[R23].

The AGM notice does not include the two section 249N resolutions. Recce's September release said that, if valid, they would go into the notice of its next general meeting at which they are eligible to be considered ^[R22]. The AGM notice does not say whether the resolutions were found valid or whether the AGM is such a meeting. The first of them, the change to the constitution, is a special resolution and would need 75 per cent of the votes cast ^[R22].

There is also a pay vote. Recce's remuneration report drew a second strike in 2024, when the spill resolution failed, and a first strike in 2025, when 19.32 per cent of votes were cast in favour of the report ^[R8]. If 25 per cent or more vote against this year's report, Resolution 11, a spill resolution, will be put to the meeting. The board recommends against it ^[R23]. If more than half the votes cast support Resolution 11, a further meeting must be held within 90 days, at which all directors except the managing director lose their seats unless they are re-elected ^[R23].

The AGM on 6 November comes about a week before the DMC meeting is expected. Shareholders will be voting on the board's make-up before they see the first independent read of the Indonesian data.

11.00 — WHAT COMES NEXT

Dates Recce has named, from the AGM to 2028

TABLE 03 lists the events Recce has named, with the document each comes from. The September quarter cash flow report had not been lodged at 22 October 2026, and it will give the first cash figure after the share purchase plan and the July tax refund.

SAMSO TAKE

In the world of antibiotics, a phrase you often hear is that the bugs always find a way. Recce's case is that R327 is the exception, a drug the bugs will struggle to beat. The laboratory work points that way, and I have no quarrel with the safety record so far. What I keep coming back to is that nobody has yet seen published results comparing R327 gel with a placebo or another treatment in patients.

The DMC in November is the first independent look. If the gel clearly beats the placebo gel and the committee says so, some of what Recce has signed comes into play. That includes the Middle East terms and one of the conditions on the Avenue money. The Arrotex licence waits on a US or European approval. If it does not, Recce still has a promising molecule and the Australian trial, and it will be working with A$2.9 million on the June quarterly report plus the July refund and share plan money, a loan and a contest over board seats.

What did the DMC recommend? If it points to a submission, will Recce publish the numbers for each group rather than a description? If the trial simply continues, the group numbers will stay sealed, as they should, and that alone would not be a bad sign. And whoever is on the board after 6 November, how will the next raising be priced, and who will take it up?

LOOK-UP BOX

The vocabulary, in plain English

Antibiotic resistance

When bacteria change so that a drug that used to kill them no longer does. Resistant bacteria survive and pass the change on.

Polymer

A large molecule made of many repeating chemical units joined in a chain. R327 is a synthetic polymer built from acrolein.

ATP

Adenosine triphosphate, the molecule every living cell uses to carry energy. Recce says R327 cuts a bacterium's ATP supply.

Repeat-exposure test

Also called serial passage. Bacteria are grown again and again in a low dose of a drug to see whether they adapt to it.

Breakpoint

The cut-off a laboratory uses to decide whether a strain of bacteria is resistant to a drug.

Diabetic foot infection (DFI)

An infected sore on the foot of a person with diabetes, graded mild, moderate or severe.

ABSSSI

Acute bacterial skin and skin structure infection, a regulators' term for serious skin infections covering at least 75 square centimetres of skin.

IWGDF/IDSA guideline

The 2023 international guideline on diabetic foot infections, from the International Working Group on the Diabetic Foot and the Infectious Diseases Society of America.

Phase 1, 2 and 3

The three stages of testing a medicine in people, from small safety studies to the large trials regulators rely on for approval.

Open-label

A trial in which everyone knows which treatment each patient is getting.

Double-blind, placebo-controlled

A trial in which neither patients nor doctors know who gets the drug and who gets an inactive look-alike, and the result is the difference between the two.

Primary endpoint

The main result a trial is designed to measure.

Interim analysis

An early look at a trial's results before it finishes.

Pivotal trial

A trial designed to support an application for approval.

Active comparator

An existing treatment that a new drug is compared with in a trial, in place of a placebo.

Data Monitoring Committee (DMC)

Independent experts who, with an independent statistician, are the only people allowed to see unblinded results while a trial runs.

Futility

A finding that a trial is unlikely to show a difference even if it runs to the end.

Non-inferiority trial

A trial that tests whether a new treatment is not worse than an existing one by more than an agreed margin.

Badan POM

Indonesia's food and drug regulator.

TGA, FDA and EMA

The medicine regulators of Australia, the United States and the European Union.

New chemical entity

A medicine whose active ingredient has never been approved before.

IND

Investigational New Drug application, filed with the FDA before a drug can be tested in a US trial.

QIDP and the GAIN Act

A US designation for antibiotics against serious infections. It adds five years to a drug's market exclusivity when the designated product is approved for the designated use.

Good Manufacturing Practice (GMP)

The quality standard regulators require for medicines made for use in people.

Special Access Scheme

A TGA pathway that lets a doctor use an unapproved medicine for an individual seriously ill patient.

Section 249N notice

A notice under the Corporations Act by which holders of at least 5 per cent of the votes, or at least 100 members, can propose resolutions for a general meeting.

Strike and spill

If 25 per cent or more of votes oppose a remuneration report at two AGMs in a row, shareholders vote on whether to call a further meeting within 90 days, at which the directors other than the managing director lose their seats unless they are re-elected.

12.00 — REFERENCES AND SOURCES

Where every figure and quotation comes from

Each source below carries a number, [R1] to [R30]. The same number appears in the text where that source is used. Click a marker in the text to land here, and click the link at the end of an entry to open the document itself.

FIG. 01, 02, 03 and 05 and PLATE 01 and 02 are reproduced from Recce's documents as lodged with the ASX, including the ASX's "For personal use only" stamp, and each caption names the document and page. FIG. 04, 06, 07, 08, 09, 10 and 11 and TABLE 01, 02 and 03 are Samso's work, drawn from the sources named in each caption. FIG. 09 is a theoretical model and is labelled as such. Samso's arithmetic in the text is labelled as Samso's wherever it appears. This piece quotes no prices at which the shares have traded, and no valuations.

[R1] Recce Pharmaceuticals Ltd, “License and Commercialisation Agreement in AUS/NZ for R327G”, ASX announcement, 22 October 2026. Link

[R2] Recce Pharmaceuticals Ltd, “Independent Review of Indonesian Phase 3 R327G Trial Data”, ASX announcement, 20 October 2026. Link

[R3] Recce Pharmaceuticals Ltd, company website pages on the mechanism of action, ABSSSI, diabetic foot infections, urinary tract infections, case studies, manufacturing, FAQ and about us, viewed 22 October 2026. Link

[R4] Recce Pharmaceuticals Ltd, “RCE Investor Presentation”, ASX announcement, 26 June 2026. Link

[R5] World Health Organization, Analysis of antibacterial agents in clinical and preclinical development, overview and analysis 2025, Geneva, 2 October 2025, data cut-off 15 February 2025. Table 2 and Annex 8. Link

[R6] Senneville É, Albalawi Z, van Asten SA et al, Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF/IDSA 2023), International Working Group on the Diabetic Foot, 2023. Link

[R7] Recce Pharmaceuticals Ltd, Annual Report 2025. Link

[R8] Recce Pharmaceuticals Ltd, “Appendix 4E and FY26 Annual Report”, ASX announcement, 31 August 2026. Link

[R9] Recce Pharmaceuticals Ltd, “Positive Regulatory Inspection Outcome for Phase 3 Trial”, ASX announcement, 21 April 2026. Link

[R10] Recce Pharmaceuticals Ltd, “HREC Approval Accelerates Global Phase 3 DFI Strategy”, ASX announcement, 22 June 2026. Link

[R11] Recce Pharmaceuticals Ltd, “HREC Approves Comparator Study for Pivotal Phase 3 DFI”, ASX announcement, 19 August 2026. Link

[R12] Recce Pharmaceuticals Ltd, “Recce Signs Middle East Licensing Term Sheet” and “Addendum to Recce Signs Middle East Licensing Term Sheet”, ASX announcements, 27 May 2026. Link

[R13] Recce Pharmaceuticals Ltd, “Quarterly Activities/Appendix 4C Cash Flow Report” for the December 2025 quarter, ASX announcement, 30 January 2026. Link

[R14] Recce Pharmaceuticals Ltd, “Quarterly Activities/Appendix 4C Cash Flow Report” for the March 2026 quarter, ASX announcement, 30 April 2026. Link

[R15] Recce Pharmaceuticals Ltd, “Quarterly Activities/Appendix 4C Cash Flow Report” for the June 2026 quarter, ASX announcement, 21 July 2026. Link

[R16] Recce Pharmaceuticals Ltd, “Appendix 4D and Interim Financial Report”, ASX announcement, 27 February 2026. Link

[R17] Recce Pharmaceuticals Ltd, announcement of the debt facility with Avenue Capital Group, ASX announcement, 17 June 2025. Link

[R18] Recce Pharmaceuticals Ltd, “Amendments to Debt Facility with Avenue Capital Group” and “Notification regarding unquoted securities”, ASX announcements, 16 October 2026. Link

[R19] Recce Pharmaceuticals Ltd, “Placement & SPP to raise $8 million”, 26 June 2026, and “Completion of Share Purchase Plan and Shortfall Notice”, 31 July 2026, ASX announcements. Link

[R20] Recce Pharmaceuticals Ltd, “AUD $3.7M Income Tax Refund Received”, 1 July 2026, and “AUD $5.3m R&D Rebate Received”, 14 January 2026, ASX announcements. Link

[R21] Recce Pharmaceuticals Ltd, “Notice of General Meeting/Proxy Form”, 31 July 2026, and “Results of General Meeting”, 2 September 2026, ASX announcements. Link

[R22] Recce Pharmaceuticals Ltd, “Resolutions under section 249N of the Corporations Act”, ASX announcement, 29 September 2026. Link

[R23] Recce Pharmaceuticals Ltd, “Notice of Annual General Meeting/Proxy Form”, ASX announcement, 7 October 2026. Link

[R24] 21 U.S. Code § 355f, Extension of exclusivity period for new qualified infectious disease products, Legal Information Institute, Cornell Law School. Link

[R25] International Diabetes Federation, IDF Diabetes Atlas, 11th edition, website viewed 22 October 2026. Link

[R26] Genetic Engineering & Biotechnology News, “Dipexium’s Diabetic Foot Ulcer Candidate Fails Phase III Trials”, 25 October 2016. Trials registered as NCT01590758 and NCT01594762. Link

[R27] Recce Pharmaceuticals Ltd, “Recce Enters Second U.S. Department of Defense R&D Agreement”, ASX announcement, 2 February 2026. Link

[R28] Recce Pharmaceuticals Ltd, “RCE Investor Webinar Presentation Deck”, ASX announcement, 19 March 2026. Link

[R29] Recce Pharmaceuticals Ltd, “Investor Webinar, Q4 FY26 Investor Presentation Deck”, ASX announcement, 21 July 2026. Link

[R30] Recce Pharmaceuticals Ltd, “General Meeting Presentation”, ASX announcement, 2 September 2026. Link

Cover photo: Recce Pharmaceuticals Annual Report 2025, page 8. Reproduced photograph, shown faded under a navy overlay on the article thumbnail.

The Samso Way – Seek the Research

Here at Samso, we pride ourselves on delivering content for investors that is independent and informed by over three decades of experience in the industry. Our content is well-researched and is only created if I see merit in discussing the company's story.

Our mission is simple. Cut through the noise and spotlight what matters. Genuine stories, grounded insights, and real opportunity.

Investors can explore our four core platforms:

• Coffee with Samso

• Samso Insights

• Samso News

• Samso Research

There may be numerous paths to success in investing, but the common thread among successful individuals is that they remain committed to making informed decisions. Equip yourself with the right knowledge and tools, and you will be well on your way to achieving your financial goals.

Most importantly, investors need to be absolutely diligent in understanding their own risk-reward tolerance and capabilities. Never bite off more than you can chew. As they say, Rome wasn't built in a day, and the Great Wall stood because it took centuries to complete.

The Samso Philosophy:

Stay curious. Stay sharp. And remember, digging deeper always uncovers the real value.

In Life, there is no such thing as a Free Lunch.

Never bite off more than you can chew is my parting comment.

Happy Investing, and the only four-letter word you need to know is DYOR.

To support our independent work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiative for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018.

Disclaimer

This article is general information only. It is not financial product advice and it does not take into account any reader's objectives, financial situation or needs. It contains no price targets, no valuations and no recommendation to buy, hold or sell any security. Companies named in this article are used as historical illustrations of events that have already occurred and no view is expressed on their current merits. Readers should consider obtaining advice from a licensed financial adviser and should conduct their own research before making any investment decision. Samso and its associates may hold interests in companies mentioned.

Read full Disclaimer.

About Samso

Samso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insights from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research.

Coffee with Samso, Samso Insights, Samso News and Samso Research are four ways into the same work. Interviews, long-form research, short takes on announcements and company-specific studies. Every one of them is about how to think about investing rather than what to buy.

Samso Insights | www.samso.com.au | An Investor Lens on ASX-Listed Companies

Samso Insights are independent research commentary for general information only. Nothing in this document is financial product advice, and it does not take into account any reader's objectives, financial situation or needs. Figures are drawn from public sources believed reliable at the stated dates but are not guaranteed; market-sensitive numbers change daily. Samso or associated parties may hold positions in, or have commercial arrangements with, companies mentioned. Seek professional advice before making investment decisions. © Samso 2026 · samso.com.au